← Back to Search

Other

Individualized Treatment for Medulloblastoma (PNOC027 Trial)

N/A

Recruiting

Led By Sabine Mueller, MD, PhD, MAS

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants must have surgically accessible disease

Participants must have recurrent medulloblastoma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years

Awards & highlights

PNOC027 Trial Summary

This trial is testing a new way to treat medulloblastoma that is based on the molecular characteristics of each person's tumor.

Who is the study for?

This trial is for children and young adults aged 12 months to 39 years with recurrent medulloblastoma, a type of brain tumor. They must have tumors that can be surgically removed, be recovering from previous treatments, and have a certain level of physical ability. Pregnant or breastfeeding women are excluded, as well as those with other cancers or serious illnesses.Check my eligibility

What is being tested?

The study tests an individualized treatment plan based on the molecular profile of each patient's tumor. It involves real-time drug screening and genomic sequencing to assign targeted therapies aimed at being effective yet less toxic.See study design

What are the potential side effects?

Since this trial uses various treatments tailored to individuals' tumors, side effects will vary widely but may include typical reactions related to chemotherapy or targeted therapy such as nausea, fatigue, hair loss, blood count changes, and increased risk of infections.

PNOC027 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My disease can be operated on.

Select...

My medulloblastoma has come back.

Select...

I meet the specific radiation requirements.

Select...

I am between 1 year and 39 years old.

Select...

I am eligible for surgery or a biopsy.

Select...

I am mostly independent and can do most activities.

PNOC027 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Median Time from tissue collection to issued treatment plan from the specialized tumor board

Secondary outcome measures

Proportion of participants with Adverse Events

PNOC027 Trial Design

1Treatment groups

Experimental Treatment

Group I: Individualized Treatment RecommendationExperimental Treatment1 Intervention

Participants will receive an individualized treatment recommendation including a combination of up to four FDA-approved drugs within 21 business days of tissue acquisition using the results of real-time high-throughput drug screening, whole exome sequencing (WES), and RNA sequencing.

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Ashion AnalyticsUNKNOWN

Washington University School of MedicineOTHER

1,935 Previous Clinical Trials

2,299,863 Total Patients Enrolled

1 Trials studying Medulloblastoma

St. Baldrick's FoundationOTHER

18 Previous Clinical Trials

9,083 Total Patients Enrolled

1 Trials studying Medulloblastoma

137 Patients Enrolled for Medulloblastoma

Media Library

Medulloblastoma Research Study Groups: Individualized Treatment Recommendation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are different sites within the city conducting this research study?

"There are a total of 4 clinical trial sites, which are located in Saint Louis, Philadelphia, San Francisco, and other locations."

Answered by AI

Are there still places available in this clinical trial for people who want to enroll?

"The trial is presently looking for candidates, as seen on clinicaltrials.gov. This study was first posted on February 22nd, 2022 and was last edited on October 5th, 2022."

Answered by AI

Are minors able to participate in this research study?

"According to the inclusion criteria set out by the researchers, people aged 12 months to 39 years old are eligible for this trial. Out of the 70 total clinical trials taking place, 13 are for people over the age of 65 and the rest are for those under 18."

Answered by AI

Could you explain the requirements for people who want to join this clinical trial?

"This study is looking for 10 participants within the ages of 12 months and 39 who currently have medulloblastoma. The following criteria must also be met:-Participants must have surgically accessible disease.-The participant must have recurrent medulloblastoma following at least one prior therapy for initial diagnosis or previous recurrence- surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy - prior to study registration.-Participants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study"

Answered by AI

How many people are being treated with the experimental medication at most?

"To move forward, this clinical trial requires 10 individuals that meet the pre-specified inclusion criteria. Those that are interested can inquire about participating at St. Louis Children's Hospital in Missouri or Children's Hospital of Philadelphia in Pennsylvania."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma

2022. "Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05057702.

All > Medulloblastoma